O 14: Differentiating Demyelinating Disorders of the Central Nervous System – a Focus on Multiple Sclerosis and Neuromyelitis-Optica Spectrum Disorders

o 14: differentiating demyelinating disorders of the central nervous system – a focus on multiple sclerosis and neuromyelitis-optica spectrum disorders

significant advances have been made in diagnosis and therapy of demyelinating disorders of the central nervous system. the most common entities of this disorders in adults – multiple sclerosis and neuromyelitis optica were initially thought to be different phenotypes of more or less the same disease. during the last ten years, this view was subsequently changed and the term neuromyelitis optica...

Is Hemorrhagic Demyelinating Lesions of Central Nervous System a Spectrum?

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate

BACKGROUND To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD). METHODS We performed a retrospective chart review of all patients with a diagnosis of NMO/NMOSD, supported by a positive NMO-IgG testing, who were treated with methotrexate. A paired sample 2 tailed t test was ...

Neuromyelitis Optica Spectrum Disorders: Diagnosis and Treatment

The last decade has witnessed rapid developments in the clinical understanding and scienti fi c foundati on of neuromyeliti s opti ca (NMO). The landmark events were the late 19th century report by Devic and Gault describing the associati on of severe acute transverse myeliti s and opti c neuriti s and the late 20th century discovery that the syndrome was associated with a specifi c autoanti bo...

Neuromyelitis optica and neuromyelitis optica-IgG seropositivity in Saudis with demyelinating diseases of the central nervous system

Background and Objective: Neuromyelitis optica (NMO) shares certain features with multiple sclerosis (MS). Similar phenotypes, wide spectrum and the differential prevalence of NMO among ethnic backgrounds pose diagnostic challenges. NMO-IgG antibodies are specific biomarker for NMO and facilitate its differentiation from other demyelinating diseases. This study aimed to assess the frequency of ...

Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications.

Several animal and human studies have implicated CD4+ T helper 17 (Th17) cells and their downstream pathways in the pathogenesis of central nervous system (CNS) autoimmunity in multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD), challenging the traditional Th1-Th2 paradigm. Th17 cells can efficiently cross the blood-brain barrier using alternate ways from Th1 cells, pro...